Premium
Artiva Biotherapeutics Inc (ARTV)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | GC Cell CorporationSociété | 1,43M | 16,50M | Achat | 11,52 | 6,00M | 31,36% |
| 2026-05-19 | Dr. Heather RaymonSVP of Research & Early Development | -3,10k | 27,88k | Vente | 9,01 | 148,23k | -2,05% |
| 2026-05-19 | Mr. Christopher P. HoranChief Technical Operations Officer | -7,00k | 63,07k | Vente | 9,01 | 293,45k | -2,33% |
| 2026-05-19 | Ms. Jennifer Kinsbruner BushCOO | -8,79k | 79,18k | Vente | 9,01 | 20,97k | -29,54% |
| 2026-05-19 | Dr. Subhashis BanerjeeChief Medical Officer | -7,04k | 63,39k | Vente | 9,01 | 144,96k | -4,63% |
| 2026-05-19 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -27,12k | 244,25k | Vente | 9,01 | 1,54M | -1,74% |
| 2026-05-11 | RA Capital Management, L.P.Société | 6,51M | 75,00M | Achat | 11,52 | 15,20M | 74,89% |
| 2026-05-11 | RA Capital Management, L.P.Société | 2,17M | 0,00 | Open Market Derivative Acquisition | 0,00 | 2,17M | - |
| 2026-05-11 | RA Capital Management, L.P.Société | 6,51M | 75,00M | Achat | 11,52 | 68,32k | -101,06% |
| 2026-02-15 | Dr. Heather RaymonSVP of Research & Early Development | -1,52k | 6,08k | Sale to Issuer | 4,00 | 151,32k | -1,00% |
| 2026-02-15 | Mr. Christopher P. HoranChief Technical Operations Officer | -2,19k | 8,75k | Sale to Issuer | 4,00 | 300,45k | -0,72% |
| 2026-02-15 | Ms. Jennifer Kinsbruner BushCOO | -3,52k | 14,06k | Sale to Issuer | 4,00 | 26,63k | -11,66% |
| 2026-02-15 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -14,60k | 58,40k | Sale to Issuer | 4,00 | 1,56M | -0,93% |
| 2025-12-15 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -3,19k | 19,12k | Automatic Disposition | 6,00 | 1,21M | -0,26% |
| 2025-11-15 | Mr. Christopher P. HoranChief Technical Operations Officer | -1,90k | 6,17k | Sale to Issuer | 3,25 | 78,18k | -2,37% |
| 2025-11-15 | Dr. Heather RaymonSVP of Research & Early Development | -1,38k | 4,47k | Sale to Issuer | 3,25 | 39,59k | -3,36% |
| 2025-11-15 | Ms. Jennifer Kinsbruner BushCOO | -3,06k | 9,93k | Sale to Issuer | 3,25 | 18,84k | -13,95% |
| 2025-11-17 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -6,38k | 21,52k | Automatic Disposition | 3,38 | 344,00k | -1,82% |
| 2025-11-15 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -6,35k | 20,63k | Sale to Issuer | 3,25 | 344,00k | -1,81% |
| 2025-11-15 | Ms. Neha KrishnamohanInitié | -3,49k | 11,34k | Sale to Issuer | 3,25 | 19,36k | -15,28% |
| 2025-10-17 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -25,50k | 153,00k | Automatic Disposition | 6,00 | 356,72k | -6,67% |
| 2025-05-15 | Mr. Christopher P. HoranChief Technical Operations Officer | -4,92k | 12,69k | Sale to Issuer | 2,13 - 2,75 | 80,08k | -5,79% |
| 2025-05-15 | Ms. Neha KrishnamohanInitié | -7,15k | 18,84k | Sale to Issuer | 2,13 - 2,75 | 15,97k | -30,94% |
| 2025-05-15 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -8,94k | 21,82k | Sale to Issuer | 2,13 - 2,75 | 382,22k | -2,29% |
| 2025-05-15 | Dr. Heather RaymonSVP of Research & Early Development | -2,38k | 6,09k | Sale to Issuer | 2,13 - 2,75 | 40,97k | -5,50% |
| 2025-08-15 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -25,50k | 69,58k | Automatic Disposition | 2,73 | 382,22k | -6,25% |
| 2025-05-15 | Ms. Jennifer Kinsbruner BushCOO | -8,35k | 21,75k | Sale to Issuer | 2,13 - 2,75 | 14,45k | -36,61% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
